18.49k followers • 27 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stocks that were bought the most by hedge funds in the last quarter.
Bristol-Myers Squibb Company
Altria Group, Inc.
General Electric Company
Vodafone Group Plc
ICICI Bank Limited
Sirius XM Holdings Inc.
Invitation Homes Inc.
Caesars Entertainment Corporation
Devon Energy Corporation
Eldorado Resorts, Inc.
Verra Mobility Corporation
Harmony Gold Mining Company Limited
United States Steel Corporation
Office Depot, Inc.
BellRing Brands, Inc.
Satsuma Pharmaceuticals, Inc.
HTG Molecular Diagnostics, Inc.
Churchill Capital Corp III
Invitation Homes Inc. (NYSE: INVH) ("Invitation Homes" or the "Company") announced today the pricing of an offering of 14,500,000 shares of Invitation Homes common stock. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $395 million. As part of the offering, Invitation Homes has granted the underwriters a 30-day option to purchase up to an additional 2,175,000 shares of common stock. The offering is expected to close on June 4, 2020, subject to customary closing conditions.
The Canadian dollar <CAD=> was trading 1.5% higher at 1.3571 to the U.S. dollar, or 73.69 U.S. cents. "It just seems like everyone wants to sell (U.S.) dollars right now," said Bipan Rai, North America head of FX strategy at CIBC Capital Markets. "The Fed has implemented many measures to make sure that the world is awash in U.S. dollars."
Invitation Homes Inc. (NYSE: INVH) ("Invitation Homes" or the "Company") announced today that it has commenced an offering of 14,500,000 shares of Invitation Homes common stock. Invitation Homes intends to grant the underwriters a 30-day option to purchase up to an additional 2,175,000 shares of common stock.
USD/CAD breached the support at 1.3730 and moved closer to 1.3600.
With the global economy showing some serious volatility, holding stocks with secure balance sheets and reliable cash flows is one way to beat the volatility and sleep easy at night. If you're looking for some stocks that effectively "print money," keep reading to see why Facebook (NASDAQ: FB), Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), and Altria (NYSE: MO) all fit the bill. It's hard to think of a bigger cash cow than Facebook.
Eldorado Resorts, Inc. (NASDAQ: ERI) ("Eldorado," "ERI," or "the Company") announced that it will resume operations at Isle of Capri Casino Hotel Boonville, Isle of Capri Casino Kansas City and Lumière Place Casino & Hotels in Missouri and at Isle Casino Hotel Bettendorf and Isle Casino Hotel Waterloo in Iowa today, Monday, June 1, 2020. With today’s reopenings in Missouri and Iowa, 11 of Eldorado’s 23 casino entertainment facilities have resumed operations following the suspension of operations in March.
Bristol Myers Squibb Announces Commercial Launch and Availability of ZEPOSIA®, a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
(Bloomberg) -- The year’s biggest meeting of cancer researchers was subjected to a coronavirus overhaul this year, but even in scaled-back form it forced investors to recalibrate their expectations for some closely watched medicines.The American Society of Clinical Oncology meeting is the field’s most important gathering each spring, providing a stage for major pharmaceutical companies to unveil major findings and tout promising treatments. It’s also an annual opportunity for all kinds of researchers, doctors, executives and investors to rub elbows.With Covid-19 making travel uncomfortable and splashy conferences impossible this year, the summit was mostly a virtual affair. Still, it delivered many of the kinds of important victories and stinging setbacks it often does. And the meeting showed that even as the drug industry races to identify virus treatments and vaccines, cancer remains perhaps its most important business overall.“When the coronavirus wanes and we have a vaccine, and this infectious disease is brought under control, we will still have cancer and the need for new treatments,” said Richard Schilsky, ASCO’s chief medical officer, in an interview. “We have millions of patients around the world who need new and improved treatments for cancer.”Among the most noteworthy winners was U.K. pharmaceutical giant AstraZeneca Plc, which reported that its blockbuster Tagrisso reduced the risk of dying from lung cancer or relapse by four-fifths over three years. The drug is already AstraZeneca’s biggest product, bringing in $982 million in sales in the first quarter alone.Some smaller drug companies also logged what looked like significant victories: Trillium Therapeutics Inc. said that a second patient taking its experimental lymphoma therapy responded to the treatment. Shares of Trillium, which has a market value of about $560 million, surged more than 17% on FridayAnd as ASCO played out, other big cancer-research news also roiled drugmaker stocks.Pfizer Inc. shares fell 5.1% in trading before U.S. exchanges opened Monday after the U.S. drug bellwether said a late-stage study of its treatment for metastatic breast cancer, Ibrance, was unlikely to show a statistically significant improvement in invasive disease-free survival for patients with early breast cancer.Though the Covid-19 pandemic has been the defining story of the health-care business this year, the ASCO meeting was a reminder that most of the world’s pharmaceutical companies remain keenly focused on finding new cancer treatments to generate profits. And that focus has paid off for patients: The U.S. death rate from cancer has been falling at a record pace, thanks largely to big advances in treating lung tumors.Data presented at the meeting showed progress in combating the second leading cause of death worldwide, Schilsky said. Researchers found medicines used for patients with advanced disease can have an even bigger benefit for those with recently diagnosed tumors, while medicines are emerging that are effective against a wide range of tumors that are driven by specific gene mutations.Deals Getting DoneLarge drugmakers have remained on the prowl for promising cancer therapies that they can acquire through mergers or other transactions. Even Gilead Sciences Inc., which has been in the headlines because of its potential coronavirus treatment remdesivir, has been getting cancer-focused deals done against the backdrop of the pandemic.Last week, Gilead agreed to work on immunotherapy drugs with biotech Arcus Biosciences Inc. And earlier this year it agreed to buy cancer-drug maker Forty Seven for $4.9 billion. Gilead has been pressured by investors to find new drugs that can take the place of some of its aging blockbusters. It made another big bet on cancer when it bought Kite Pharma and its drug Yescarta, though sales of the highly priced genetic therapy have so far failed to live up to expectations.At ASCO, Gilead presented encouraging new data on magrolimab, an immunology drug that was developed by Forty Seven, a sign that the company’s wager could pay off. Gilead’s management is successfully building a pipeline of potential new therapies, Jefferies & Co. analyst Michael Yee said in a note sent to clients.Gilead shares dropped 1.5% early Monday. They now have gained about 20% so far this year, in part because of excitement over remdesivir.Breakthroughs at ASCO could make smaller companies enticing to Gilead and to other giants looking to add to their rosters of experimental therapies. Adaptimmune Therapeutics Plc’s U.S.-traded shares more than doubled in value after the company presented early studies for therapies that could treat a number of cancers, including lung and head and neck tumors.Allogene Therapeutics Inc., which is developing a CAR-T therapy similar to Yescarta, gained 3.5% Friday after it said its treatment benefited 63% of patients with blood cancer in an early-stage trial. Allogene’s founders ran Kite Pharma before selling it to Gilead for $11 billion in 2017.Dueling GiantsLike Gilead, Bristol-Myers Squibb Co. has also sought to refashion itself into a cancer-fighting juggernaut, mostly notably with its $74 billion takeover of Celgene Corp. last year. Even before that transaction, the company was locked in a battle with rival Merck & Co. for supremacy in the market for lung-cancer immunotherapies.Merck’s Keytruda and Bristol-Myers’s Opdivo are blockbusters for each company, and the drugmakers have raced to expand their use in a range of tumor types. But at ASCO, a study of Opdivo in combination with another Bristol-Myers drug, Yervoy, supported what JPMorgan Chase & Co. analyst Chris Schott said in a note was a “niche role” in treating certain lung-cancer patients -- not one that will upset Keytruda’s dominance.Bristol-Myers shares declined 0.2% on Friday, while Merck advanced 2.1%. Both were little changed before U.S. markets opened Monday.Last year, Opdivo generated $7.2 billion in revenue for Bristol-Myers, while Yervoy brought in $1.5 billion. Together, the two drugs accounted for roughly a third of the company’s sales. Meanwhile, Keytruda generated $11 billion for Merck, about 24% of its sales.Another challenge to Keytruda may come from Switzerland’s cancer titan Roche Holding AG. The drugmaker presented data at ASCO showing that combining the experimental tiragolumab with one of its proven medicines, Tecentriq, worked better than prescribing Tecentriq alone in patients with metastatic non-small-cell lung cancer. The phase 2 data suggests it “could potentially compete with Merck’s Keytruda in a segment of lung-cancer patients,” wrote Cinney Zhang of Bloomberg Intelligence.Some Chinese drugmakers also showed promising findings in liver cancer. A combination from Innovent Biologics Inc. showed initial efficacy comparable to Roche in hepatocellular carcinoma, for which China accounts for almost than half of new cases. Innovent shares surged 10% in Hong Kong trading Monday.(Updates with share moves for Pfizer, Gilead and Innovent in eighth, 14th and last paragraphs)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
SOUTH SAN FRANCISCO, Calif., June 01, 2020 -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported completion of enrollment.
* Real drops as economic outlook deteriorates * Colombian central bank minutes expected * Brazilian, Mexican manufacturing PMI come off record lows in May (Adds details, updates prices) By Susan Mathew and Ambar Warrick June 1 (Reuters) - Latin American stocks rose on Monday, tracking their global peers amid some relief over Sino-U.S. tensions, while Brazil's real fell on further concerns over the country's economic outlook. Surging iron ore prices buoyed Brazilian mining giant Vale , while planemaker Embraer SA rose after it said China and India could be new partners after its deal with Boeing Co fell apart.
Antipodes Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Antipodes Global Fund posted a return of -5.3% for the quarter, outperforming its benchmark, the MSCI AC World Net Index which returned -9.7% in the same quarter. You should check out Antipodes Partners top 5 stock picks […]
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
In this article we will check out the progression of hedge fund sentiment towards Eldorado Resorts Inc (NYSE:ERI) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]
Bluware Corp, the digital innovation platform that enables the oil and gas industry to accelerate digital transformation initiatives using deep learning, is pleased to announce a new agreement with BP (NYSE: BP). Bluware's technology will help BP to improve quality and speed when delivering seismic interpretation products.
Brazil's real swung between looses and gains, while Chile's peso traded flat against a weaker dollar. As oil prices declined, Colombia's peso lost 0.1%. Mexico's peso firmed 0.7% in line with broader emerging market peers which rallied on hopes of an economic recovery as governments ease restrictions that were imposed on economic activity to contain the spread of the novel coronavirus.
Most people know by now that (GE) sold its iconic lighting business last week. “I bought a home-automation system and nothing worked,” Savant CEO Robert ‘Bob’ Madonna said in an interview. On the other hand, “GE is DIY,” or do it yourself, Madonna said.
Devon Energy (DVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The first step for any decision on Chinese telecoms company Huawei is for Britain's National Cyber Security Centre (NCSC) to finish its work on the impact of U.S. sanctions, a spokesman for British Prime Minister Boris Johnson said on Monday. "The first thing that we need to do is to allow the NCSC to complete its work on the impact of the sanctions, that's ongoing."
The company produced expectation-beating results. The acquisition of Celgene has gone very well, but shares trade with a multiple of less than 10 times earnings Continue reading...